Howard Kaufman, MD, FACS, MBA
Chief Medical Officer
Replimune Group, Inc.
Dr. Kaufman is the Chief Medical Officer of Replimune Ltd, and additionally holds roles as the Entrepreneur-in-Residence at Atlas Ventures and the Medical Director of the Cancer Center at Pasadena Hospital Association. Prior to his role at Replimune, Dr. Kaufman served as the Chief of Surgical Oncology at the Albert Einstein College of Medicine, the Chief of Surgical Oncology at Columbia University, and Associate Director of the Herbert Irving Comprehensive Cancer Center.
Dr. Kaufman was a pioneer in the development of recombinant viruses for cancer therapy and through research at the tumor vaccine program at the National Cancer Institute (NCI) developed the first vaccinia virus to express a human tumor antigen in 1988. His work also contributed significantly to the clinical development of the first oncolytic immunotherapy approved by the FDA for the treatment of cancer, (talimogene laherparepvec, Imlygic). Dr. Kaufman has held multiple leadership positions for various biotechnology companies and research groups and serves as a Member of the Clinical Advisory Board at IFM Therapeutics, Inc. and a Member of the Scientific Advisory Board at Neogenix Oncology, Inc. He is a member of numerous professional societies and was President of the Society for Immunotherapy of Cancer (SITC) from 2014 to 2016 .
Dr. Kaufman has published over 500 peer-reviewed scientific papers, books, review articles, and abstracts, and has been the recipient of several awards including the Daland Prize and the Humanitarian Award from the Melanoma Research Foundation. He completed his undergraduate studies at the University of Illinois Chicago and received his medical degree at Loyola University.